Retatrutide (Reta) Side Effects: What Trials Reported
Retatrutide is not approved. Here are the adverse events reported in its clinical trials, with the sources.
:format(webp))
Retatrutide is not approved by the FDA and has not been proven safe or effective for any treatment. This article is for educational purposes only and does not recommend or encourage the use of this substance. NiceRx does not offer or prescribe retatrutide.
Retatrutide is an investigational drug that acts as a triple agonist at GLP-1, GIP, and glucagon receptors, Lilly says. It has not been approved by the FDA, and its safety is still being studied.
Currently, retatrutide is in phase 3 clinical trials. A study published in the New England Journal of Medicine reports the adverse events seen in the phase 2 clinical trial.
This article summarizes the adverse events reported in published retatrutide clinical trials and in Lilly's trial announcements, and what is not yet known. Retatrutide is an investigational (not yet approved) medication and its long-term safety is still being studied.
What is retatrutide?
Retatrutide is an investigational once-weekly injectable triple agonist that targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors (GCG receptors) simultaneously, Lilly says.
A phase 2 clinical trial, published in The New England Journal of Medicine, included 338 adults with a body mass index (BMI) of 30 or greater, or a BMI between 27 and 30, with at least one weight-related condition. Participants were assigned to receive weekly doses of retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg for 48 weeks, or placebo. The report says the most common adverse events were gastrointestinal.
In TRIUMPH-1, the NEJM report says 2,339 adults with obesity without diabetes were randomized to retatrutide 4 mg, 9 mg or 12 mg, or placebo, once weekly for 80 weeks, and that the most common adverse events were gastrointestinal.
The most common retatrutide side effects
In the Phase 2 trial, the report says the gastrointestinal events were dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose (2 mg compared with 4 mg).
Lilly says the most common adverse events in its Phase 3 trials were consistent with the types of adverse events seen in clinical trials for other incretins.
Nausea
Nausea was the most frequently reported adverse event in TRIUMPH-4. Lilly reports nausea in 38.1% of participants taking retatrutide 9 mg and 43.2% taking 12 mg, compared with 10.7% with placebo.
Diarrhea
In TRIUMPH-4, Lilly reports diarrhea in 34.7% (9 mg) and 33.1% (12 mg) of participants taking retatrutide, compared with 13.4% with placebo. The tables below give the TRIUMPH-2 rates.
Vomiting
In TRIUMPH-4, Lilly reports vomiting in 20.4% (9 mg) and 20.9% (12 mg) of participants taking retatrutide, compared with 0.0% with placebo.
Constipation
In TRIUMPH-4, Lilly reports constipation in 21.8% (9 mg) and 25.0% (12 mg) of participants taking retatrutide, compared with 8.7% with placebo.
Decreased appetite
Decreased appetite was among the commonly reported adverse events. In TRIUMPH-4, Lilly reports it in 19.0% (9 mg) and 18.2% (12 mg) of participants taking retatrutide, compared with 9.4% with placebo.
Dysesthesia
Dysesthesia was reported more often with retatrutide than with placebo. In TRIUMPH-4, Lilly reports it in 8.8% (9 mg) and 20.9% (12 mg) of participants taking retatrutide, compared with 0.7% with placebo, and says these events were generally mild and rarely led to treatment discontinuation.
Other adverse events reported in the trials
In TRIUMPH-2, the Lancet report says hypotension was more frequent with retatrutide than with placebo: 4 (1%), 14 (5%) and 18 (6%) participants in the 4 mg, 9 mg and 12 mg groups, compared with 1 (less than 1%) with placebo. Lilly reports urinary tract infections in TRIUMPH-2 in 3.8%, 6.3% and 8.0% of participants taking retatrutide, compared with 6.6% with placebo.
In the Phase 2 trial, the report says dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.
In the Phase 2 trial in people with type 2 diabetes, the report says mild-to-moderate gastrointestinal adverse events, including nausea, diarrhea, vomiting and constipation, occurred in 35% of retatrutide participants (13% to 50% across groups, with the highest rate in the 8 mg fast escalation group), compared with 13% with placebo and 35% with dulaglutide 1.5 mg, and that there were no reports of severe hypoglycemia and no deaths.
Frequency of retatrutide side effects
Lilly reports these adverse event rates for TRIUMPH-2, an 80-week trial in adults with obesity or overweight and type 2 diabetes. They are topline figures from a news release.
Adverse event (TRIUMPH-2) | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
Diarrhea | 27.4% | 33.5% | 33.6% | 13.2% |
Nausea | 13.7% | 20.8% | 28.0% | 8.0% |
Constipation | 14.0% | 16.2% | 16.8% | 9.4% |
Decreased appetite | 5.8% | 12.3% | 17.1% | 4.5% |
Vomiting | 5.5% | 10.2% | 15.7% | 4.2% |
Dysesthesia | 4.5% | 5.6% | 7.3% | 0.7% |
Urinary tract infection | 3.8% | 6.3% | 8.0% | 6.6% |
Lilly reports these adverse event rates for TRIUMPH-4, a 68-week trial in adults with obesity or overweight and knee osteoarthritis, in a news release.
Adverse event (TRIUMPH-4) | 9 mg | 12 mg | Placebo |
|---|---|---|---|
Nausea | 38.1% | 43.2% | 10.7% |
Diarrhea | 34.7% | 33.1% | 13.4% |
Constipation | 21.8% | 25.0% | 8.7% |
Vomiting | 20.4% | 20.9% | 0.0% |
Decreased appetite | 19.0% | 18.2% | 9.4% |
Dysesthesia | 8.8% | 20.9% | 0.7% |
Discontinuations and deaths reported in the trials
Discontinuation because of adverse events was higher with retatrutide than with placebo in the Phase 3 trials Lilly has reported. In TRIUMPH-4, the rates were 12.2% (9 mg) and 18.2% (12 mg), compared with 4.0% with placebo, and Lilly says they correlated with baseline BMI and included discontinuations for perceived excessive weight loss. In TRIUMPH-2 they were 3.8% (4 mg), 11.6% (9 mg) and 7.7% (12 mg), compared with 4.9% with placebo, and in TRIUMPH-3 9.8% (9 mg) and 13.5% (12 mg), compared with 4.8% (Lilly).
In TRIUMPH-2, the Lancet report says two participants died in the retatrutide 4 mg group, three in the 9 mg group, one in the 12 mg group and one in the placebo group, and that the investigators deemed all of the deaths unrelated to the study intervention.
Safety information for an approved medicine in the same class
Retatrutide has no approved safety information. For reference only, the safety summary for Zepbound (tirzepatide), an approved medicine that acts on the GIP and GLP-1 receptors, appears in Lilly's July 2026 release. It says the following. None of this has been proven for retatrutide:
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss and heartburn.
Zepbound may cause tumors in the thyroid, including thyroid cancer, and it should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Diarrhea, nausea and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. The summary says it is important to drink fluids to help reduce the chance of dehydration, and to tell a healthcare provider right away about nausea, vomiting or diarrhea that does not go away.
Gallbladder problems have happened in some people who use Zepbound. Symptoms may include pain in the upper stomach area, fever, yellowing of the skin or eyes, or clay-colored stools.
Inflammation of the pancreas (pancreatitis): the summary says to stop using Zepbound and call a healthcare provider right away for severe pain in the stomach area that will not go away, with or without nausea or vomiting. The pain may be felt from the abdomen to the back.
Serious allergic reactions: the summary says to stop using Zepbound and get medical help right away for symptoms such as swelling of the face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar: the risk may be higher when Zepbound is used with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Dose escalation in the trials
In the Phase 2 trial, the report says gastrointestinal events were partially mitigated with a lower starting dose (2 mg compared with 4 mg). In Lilly's Phase 3 trials, participants started at 2 mg once weekly and the dose was increased every four weeks to the study's target dose. The dosage chart article lists the doses the trials used.
Retatrutide and other incretin medicines: adverse events
Lilly says the most common adverse events with retatrutide in its Phase 3 trials were consistent with the types of adverse events seen in clinical trials for other incretins.
A 2025 systematic review of three retatrutide trials (510 participants given retatrutide and 130 given placebo) reported that gastrointestinal adverse effects were the most commonly reported.
What we don’t know yet: Long-term safety
Retatrutide is still in phase 3 clinical trials, and its long-term safety has not been established.
Currently, the medication is in phase 3 clinical trials. Clinicians and patients should not assume the full safety profile yet unless the medication receives FDA approval. The manufacturer, Eli Lilly, says retatrutide is in the TRIUMPH phase 3 development program, and plans to submit a Biologics License Application to the FDA in the first quarter of 2027.
Frequently asked questions
How long do retatrutide side effects last?
The sources reviewed for this article do not give a general duration for gastrointestinal adverse events. Lilly says the dysesthesia and urinary tract infection events in TRIUMPH-2 and TRIUMPH-3 were generally mild to moderate, and the majority resolved during treatment.
What is the most common side effect of retatrutide?
In the trials, the most commonly reported adverse events were gastrointestinal. In TRIUMPH-4, nausea was the most frequent one that Lilly reports in 38.1% (9 mg) and 43.2% (12 mg) of participants taking retatrutide, compared with 10.7% with placebo.
Are there serious risks?
Retatrutide has not been proven safe, and its long-term safety is unknown. In the Phase 3 trials Lilly has reported, discontinuation because of adverse events was higher with retatrutide than with placebo. In TRIUMPH-2, deaths occurred in both the retatrutide and placebo groups, and the investigators deemed all of them unrelated to the study intervention, the Lancet report says.
Is retatrutide safe?
Retatrutide has not been approved by the FDA. The FDA states it has not been found safe and effective for any condition. Lilly says it is being studied in Phase 3 clinical trials.
When should I contact my doctor about side effects?
If you have taken a product sold as retatrutide and develop a health problem, contact a licensed clinician or seek medical care promptly. You can also report a problem to the FDA through MedWatch, the FDA’s safety information and adverse event reporting program.
Can I get retatrutide now?
Lilly says retatrutide is legally available only to participants in its clinical trials. The medication is not available at pharmacies. The FDA states that retatrutide cannot be used in compounding, so products sold online as retatrutide are not FDA-approved.
Conclusion: What is known about retatrutide side effects
Retatrutide is an investigational drug. Lilly says the most common adverse events in its Phase 3 trials were consistent with those seen in clinical trials for other incretins.
In the trials reported so far, nausea, vomiting, diarrhea, constipation and decreased appetite were commonly reported adverse events, and the Phase 2 report says the gastrointestinal events were dose-related.
Long-term safety data for retatrutide are not yet available. Ongoing phase 3 trials are collecting more safety data. Retatrutide is not approved by the FDA.
Retatrutide is not approved by the FDA and has not been proven safe or effective for any treatment. This article is for educational purposes only and does not recommend or encourage the use of this substance. NiceRx does not offer or prescribe retatrutide.
Sources (14)
FDA: Concerns with unapproved GLP-1 drugs used for weight loss
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-lossEli Lilly news release, July 23, 2026: retatrutide results in two additional Phase 3 trials
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additionalEli Lilly news release, December 11, 2025: retatrutide Phase 3 results
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-averageNew England Journal of Medicine: TRIUMPH-1 trial report (retatrutide)
https://www.nejm.org/doi/full/10.1056/NEJMoa2604169FDA MedWatch: Safety information and adverse event reporting program
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-programNational Cancer Institute: Definition of adverse event
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adverse-eventClinicalTrials.gov: TRIUMPH-1 (NCT05929066)
https://clinicaltrials.gov/study/NCT05929066ClinicalTrials.gov: TRIUMPH-2 (NCT05929079)
https://clinicaltrials.gov/study/NCT05929079ClinicalTrials.gov: TRIUMPH-3 (NCT05882045)
https://clinicaltrials.gov/study/NCT05882045ClinicalTrials.gov: TRIUMPH-4 (NCT05931367)
https://clinicaltrials.gov/study/NCT05931367Journal of Basic and Clinical Physiology and Pharmacology: Efficacy and safety of retatrutide for the treatment of obesity, a systematic review of clinical trials
https://pubmed.ncbi.nlm.nih.gov/40728138/The Lancet: Retatrutide for people with type 2 diabetes, a phase 2 trial conducted in the USA
https://pubmed.ncbi.nlm.nih.gov/37385280/The New England Journal of Medicine: Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972The Lancet: Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2), a phase 3 trial
https://pubmed.ncbi.nlm.nih.gov/42810372/
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.
See if NiceRx is right for you
Personalized care, built around you.
Start your assessment:format(webp))
:format(webp))
:format(webp))